| scholarly article | Q13442814 |
| P2093 | author name string | Paul M. Roman | |
| Hannah K. Knudsen | |||
| Carrie B. Oser | |||
| P2860 | cites work | Barriers to the use of medications to treat alcoholism. | Q30335778 |
| Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors | Q31041707 | ||
| Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives | Q31808702 | ||
| Pharmacological treatment of alcohol dependence: a review of the evidence | Q33596810 | ||
| Client and counselor attitudes toward the use of medications for treatment of opioid dependence | Q33763021 | ||
| Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs | Q33817446 | ||
| Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research | Q34091192 | ||
| Strategies for disseminating evidence-based practices to staff who treat people with serious mental illness | Q34451164 | ||
| Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers. | Q34711509 | ||
| Effect of primary medical care on addiction and medical severity in substance abuse treatment programs | Q34740918 | ||
| Bridging the gap: a hybrid model to link efficacy and effectiveness research in substance abuse treatment | Q35074748 | ||
| The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters | Q35792939 | ||
| Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs | Q36213324 | ||
| Medications development: successes and challenges | Q36220137 | ||
| Disseminating evidence-based practices in substance abuse treatment: a review with suggestions. | Q36524545 | ||
| Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. | Q36627877 | ||
| Trends in the adoption of medications for alcohol dependence | Q36657732 | ||
| Role of state policies in the adoption of naltrexone for substance abuse treatment | Q36741375 | ||
| Trends in comprehensive service availability in outpatient drug abuse treatment | Q36889947 | ||
| A categorical typology of naltrexone-adopting private substance abuse treatment centers | Q37193168 | ||
| Can the national addiction treatment infrastructure support the public's demand for quality care? | Q38463629 | ||
| Organizational correlates of access to primary care and mental health services in drug abuse treatment units | Q39484121 | ||
| The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment | Q40201753 | ||
| Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability | Q40358105 | ||
| The future of the nurse shortage: will wage increases close the gap? | Q40546589 | ||
| Economic and demographic trends signal an impending physician shortage | Q40652615 | ||
| Adoption and implementation of new technologies in substance abuse treatment. | Q44033265 | ||
| Research to practice: adoption of naltrexone in alcoholism treatment | Q44368411 | ||
| Physicians’ opinions about medications to treat alcoholism | Q44444191 | ||
| Understanding US addiction physicians' low rate of naltrexone prescription | Q44574555 | ||
| Smoking cessation services in U.S. methadone maintenance facilities | Q45144526 | ||
| Crossing the Quality Chasm: A New Health System for the 21st Century. | Q46038913 | ||
| Racial and ethnic disparities in SSRI availability in substance abuse treatment | Q46393288 | ||
| Adoption of naltrexone to treat alcohol dependence | Q46460780 | ||
| The gap between research and practice in substance abuse treatment | Q46554699 | ||
| Dimensions of publicness and performance in substance abuse treatment organizations | Q47193407 | ||
| Modeling the use of innovations in private treatment organizations: the role of absorptive capacity | Q47293358 | ||
| A survey of clinical practices and readiness to adopt evidence-based practices: Dissemination research in an addiction treatment system | Q48542148 | ||
| Shattuck lecture--clinical research to clinical practice--lost in translation? | Q48569309 | ||
| State policies matter: the case of outpatient drug treatment program practices. | Q50143335 | ||
| Provision of on-site medical care to patients with hepatitis C in drug treatment units. | Q51935850 | ||
| The economics of public health: financing drug abuse treatment services. | Q51945348 | ||
| Adolescent and young adult heroin patients: drug use and success in methadone maintenance treatment. | Q51979577 | ||
| The federal role in drug abuse technology transfer: a history and perspective. | Q53430425 | ||
| A conceptual framework for transferring research to practice | Q74318938 | ||
| Medscape's response to the Institute of Medicine Report: Crossing the quality chasm: a new health system for the 21st century | Q74494882 | ||
| A discussion of the concept of technology transfer of research-based drug "abuse" prevention and treatment interventions | Q74614674 | ||
| What's next for translation research? | Q79989370 | ||
| ORGANIZATIONAL INNOVATION: A META-ANALYSIS OF EFFECTS OF DETERMINANTS AND MODERATORS | Q99301494 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 99-107 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Journal of Addiction Medicine | Q15752435 |
| P1476 | title | Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations | |
| Facilitating Factors and Barriers to the Use of Medications in Publicly Funded Addiction Treatment Organizations | |||
| P478 | volume | 4 |
| Q35075932 | A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation |
| Q36025907 | Access to Addiction Pharmacotherapy in Private Health Plans |
| Q50636153 | Addiction treatment staff perceptions of training as a facilitator or barrier to implementing evidence-based practices: a national qualitative research study. |
| Q35447234 | Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs |
| Q35042742 | Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure |
| Q35490468 | Barriers to use of pharmacotherapy for addiction disorders and how to overcome them |
| Q36934945 | Counselor training and attitudes toward pharmacotherapies for opioid use disorder. |
| Q37607166 | Dentists United to Extinguish Tobacco (DUET): a study protocol for a cluster randomized, controlled trial for enhancing implementation of clinical practice guidelines for treating tobacco dependence in dental care settings |
| Q36597560 | Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States. |
| Q37729024 | Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders |
| Q34570585 | Examining the sustainment of the Adolescent-Community Reinforcement Approach in community addiction treatment settings: protocol for a longitudinal mixed method study. |
| Q36381418 | Financial factors and the implementation of medications for treating opioid use disorders |
| Q33675540 | First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario |
| Q37684474 | Implementing drug abuse treatment services in criminal justice settings: Introduction to the CJ-DATS study protocol series |
| Q30366758 | Innovation attributes and adoption decisions: perspectives from leaders of a national sample of addiction treatment organizations. |
| Q38871371 | Integration of Care in the Implementation of the Affordable Care Act: Changes in Treatment Services in a National Sample of Centers Treating Substance Use Disorders. |
| Q58108153 | Medications for Alcohol Use Disorders in a Primary Care Practice-Based Research Network Implementation Study |
| Q34777438 | Nurse turnover in substance abuse treatment programs affiliated with the National Drug Abuse Treatment Clinical Trials Network |
| Q36129595 | Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs |
| Q36192673 | Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders |
| Q35937004 | Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations |
| Q36643013 | Rural substance use treatment centers in the United States: an assessment of treatment quality by location |
| Q46830109 | State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder. |
| Q36494890 | The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study |
| Q33716545 | The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation |
| Q37425100 | The employment of nurses in publicly funded substance abuse treatment programs |
| Q37729027 | The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources |
| Q34925449 | Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation |
Search more.